MAP2K1 and adenocarcinoma: The screening for mutations on a Sequenom MassARRAY platform did not show any mutations in the 10 examined genes (ALK, BRAF, DDR2, EGFR, ERBB2, KRAS, MAP2K1, NRAS, PIK3CA, RET) in the DALM or in the first adenocarcinoma removed a few years before the kidney transplant.